Precision Medicine
for Everyone

We combine multi-modal molecular profiling, clinical-grade databases, and AI to deliver actionable precision intelligence

Request a Demo Learn More
Helyra Clinical Intelligence Report
Oncology
Cardiology
Neurology
Endocrinology
Dermatology
Gastro
Immunology
Ophthalmology
Reproduction
Oncology — filtered
BRCA2 — Carrier, Elevated Breast/Ovarian Risk Recommend: genetic counseling referral
DPYD I560S — Fluoropyrimidine Toxicity Risk Avoid: 5-FU, capecitabine at standard doses
Colorectal Cancer — 107 GWAS Variants Research association — recommend screening
AI Clinical Synthesis AI-Generated
Cross-Finding Analysis

The patient's BRCA2 carrier status, combined with the DPYD I560S variant, creates a complex oncological pharmacogenomic profile requiring careful treatment planning. The BRCA2 heterozygous variant confers approximately 45% lifetime breast cancer risk and 11-17% ovarian cancer risk, while the DPYD deficiency substantially increases toxicity risk from fluoropyrimidine-based chemotherapy regimens.

Critically, these two findings interact: if the patient were to develop a BRCA2-associated malignancy requiring chemotherapy, standard fluoropyrimidine protocols would be contraindicated without dose reduction of at least 50%. The GWAS colorectal cancer association (107 variants) adds a third dimension — colonoscopy screening should be initiated earlier than standard guidelines suggest.

The inflammatory markers (TNF-alpha carrier, IL-6 heterozygous) may further modulate cancer risk through chronic low-grade inflammation, creating a potential surveillance priority that spans multiple disciplines.

Confirmatory Tests
BRCA2 full sequencing with MLPA
DPD enzyme activity assay
Supplements
L-Methylfolate 400-800mcg daily
Vitamin D3 2000-4000 IU daily
Substances to Avoid
Fluoropyrimidines at standard dose
Synthetic Folic Acid
How It Works

From sequence to actionable intelligence.

01

Test

Your blood is processed by state of the art machines that yield gigabytes of genomic, transcriptomic, epigenetic and proteomic data.

02

Analyze

Our deterministic pipeline queries 12+ clinical databases and runs multi-model AI synthesis across 11 medical disciplines. No hallucination — every finding is database-verified.

03

Report

Your physician receives a comprehensive clinical intelligence report with discipline-separated findings, evidence tiers, and a personalized treatment plan.

71.7M+
Variant
predictions
762K+
GWAS trait
associations
2,159
Drug-gene
guidelines
11
Medical
disciplines
9
Pipeline
stages
Technology

Built on open science.
Assembled as proprietary intelligence.

Helyra's clinical engine is built entirely on commercially-clean, peer-reviewed data sources. No non-commercial databases. No licensing risk. HIPAA and FDA compliant.

What makes it proprietary is the assembly: our contraindication logic, supplement knowledge base, variant registry, composite risk evaluator, and the deterministic skeleton builder that converts raw genomic data into structured clinical findings — without any LLM involvement in the safety-critical path.

Our wellness recommendation engine draws from a curated database of evidence-backed health interventions — each validated against PubMed literature and matched to the patient's specific molecular profile, symptoms, and blood panel. Personalized wellness guidance grounded in science, not trends.

Variant Pathogenicity 4.4M variants
Missense Pathogenicity Scoring 71.7M predictions
GWAS Genome Scan 762K associations
Drug Interaction Analysis 2,159 guidelines
Supplement-Gene Analysis 39 supplements
Contraindication Enforcement 373 rules
Multi-Model AI Synthesis 5 specialist agents
Adversarial Review Red team + revision
Clinical Report 11 disciplines
Our Mission

To bring precision and preventive medicine to the masses

Making precision intelligence as accessible and routine as a standard blood test